The history of drug therapy for obesity is littered with compounds that were marginally effective for weight loss but had unacceptable side effects. Most recently, rimonabant was barred from the U ...
Further studies should include broader populations and head-to-head comparisons of bupropion/naltrexone with other active weight-loss agents. An editorialist warns that known psychiatric and ...